ECTRIMS 2019: Natalizumab usage in Denmark

Jeppe Romme Christensen | ECTRIMS 2019 | 12. September 2019

Speaker: Jeppe Romme Christensen

This study reports that natalizumab treatment has been broadly employed and usage appears to be in accordance with the approved indication in Europe. Natalizumab treatment termination typically results from JC virus status or anti-natalizumab antibodies and very infrequently due to lack of efficacy and adverse events. Most treatment switches from natalizumab are to other high-efficacy therapies.